A PYMNTS Company

US: FTC accuses Shire ViroPharma of antitrust law violations

By  |  February 15, 2017

The Federal Trade Commission announced Feb. 7 the filing of a complaint against Shire ViroPharma in federal district court.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The FTC alleges the defendants violated antitrust laws by abusing government processes to delay generic competition to its branded prescription drug, Vancocin HCl capsules.

    The Federal Drug Administration (FDA) has a practice where it refrains from approving generic applications of a drug if there are any pending citizen petition filings. ViroPharma purportedly used this to its advantage and submitted 43 filings with the FDA to delay the process for generic versions of its drug.

    “I have long advocated that the commission target abuses of government processes that significantly harm competition and consumers. The commission’s action is another example of this ongoing commitment,” said FTC acting chairwoman Maureen K. Ohlhausen.

    Full Content: Legal News Line

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.